Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo

Antiviral Research

Volumn 49, Issue 3, 2001, Pages 179-189

  Weber, Olaf ^a,b   Bender, Wolfgang ^a   Eckenberg, Peter ^a   Goldmann, Siegfried ^a   Haerter, Michael ^a   Hallenberger, Sabine ^a   Henninger, Kerstin ^a   Reefschläger, Jürgen ^a   Trappe, Jörg ^a   Witt Laido, Astrid ^a   Ruebsamen Waigmann, Helga ^a  

^a BAYER AG   (Germany)

^b BAYER CORPORATION   (United States)

Author keywords

Animal models; Antiviral activity; Human cytomegalovirus; Murine cytomegalovirus

Indexed keywords

3 HYDROXY 2,2 DIMETHYL N [4[[[5 (DIMETHYLAMINO) 1 NAPHTHYL]SULFONYL]AMINO]PHENYL]PROPANAMIDE; ANTIVIRUS AGENT; GANCICLOVIR; TOMEGLOVIR; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CYTOMEGALIC INCLUSION BODY DISEASE; CYTOMEGALOVIRUS; FEMALE; HUMAN CYTOMEGALOVIRUS; IMMUNE DEFICIENCY; IN VIVO STUDY; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; ORGAN DISTRIBUTION; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS INHIBITION;

ANIMALS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; HUMANS; KIDNEY; LIVER; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; MICE, INBRED NOD; MICE, SCID; NAPHTHALENESULFONATES; NUCLEIC ACID HYBRIDIZATION; PRODRUGS; SALIVARY GLANDS;

ANIMALIA; CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5; MAIZE CHLOROTIC MOTTLE VIRUS; MOUSE CYTOMEGALOVIRUS 1; MURINAE;

EID: 0035050725     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(01)00127-9     Document Type: Article

References (34)

1. Chronic intrauterine and perinatal infections
2. Metabolic activation of the nucleoside analogg 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus
3. Adoptive transfer of diabetes into immunodeficient NOD-scid/Scid mice. Relative contributions of CD4+ and CD8+ cells from diabetic versus prediabetic NOD.NON-Thy-1a donors
4. Summary of the II International Symposium on Cytomegalovirus
5. Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation - A prospective derivation and validation cohort analysis
6. Activity of 9-(1,3-dihydroxy-2-propxymethyl)guanine compared with that of acyclovir against human monkey and rodent cytomegaloviruses
7. Inhibition of human cytomegalovirus replication by a novel nonnucleosidic compound - Mechanism of antiviral action
8. Genetic analysis of a clinical isolate of human cytomegalovirus exhibiting resistance against both ganciclovir and cidofovir
9. In vivo drug screening applications of HIV-infected cells cultivated within hollow fibers in two physiologic compartments of mice
10. In vivo cultivation of tumor cells in hollow fibers
11. Ocular manifestations of HIV infection
12. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis
13. Value of animal models to evaluate agents with potential activity against human cytomegalovirus
14. Murine cytomegalovirus infection as a model for determining potential efficacy of antivirals in human disease
15. Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient
16. Resistance to antiviral drugs
17. Effect of acyclovir and phosphonoformate on cytomegalovirus infection in guinea pigs
18. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl) guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice
19. Activity of the anti-HIV agent 9-(2-phosphonyl-methoxyethyl)-2,6-diaminopurine against cytomegalovirus in vitro and in vivo
20. Lack of MHC class I complex expression has no effect on spread and control of cytomegalovirus infection in vivo
21. The nonobese diabetic scid mouse: Model for spontaneous thymomagenesis associated with immunodeficiency
22. Novel non-nucleosidic inhibitors of cytomegalovirus - Antiral activity in vitro
23. Impact of cytomegalovirus infection on organ transplant recipients
24. Double resistance to ganciclovir and foscarnet of 4 human cytomegalovirus strains recovered from AIDS patients
25. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice
26. Intracellular metabolism and enzymatic phosphorylation of 9-(1,3-dihydroxy-2-propoxymethyl)guanine and acyclovir in herpes simplex virus-infected and uninfected cells
27. Treatment of murine cytomegalovirs infections in severe combined immunodeficient mice with ganciclovir, (s)-1-[3-hydroxy-2-(phoshonylmethoxy) propyl]cytosine, interferon, and Bropirimine
28. Nucleotide analogs related to acyclovir and ganciclovir are effective against murine cytomegalovirus infections in BALB/c and severe combined immunodeficient mice
29. Antiviral activities of nucleosides and nucleotides against wild-type and drug-resistant strains of murine cytomegalovirus
30. Congenital cytomegalovirus infection: The relative importance of primary and recurrent maternal infections
31. Cytomegalovirus and the aquired immunodeficiency syndrome
32. Novel mouse models for the investigation of experimental drugs with activity against human varicella-zoster virus
33. Natural killer (NK) cell response in mice with severe combined immunodeficiency. The stimulation of NK cells and the NK cell-dependent control of virus infectins occur independently of T and B cell function
34. Efficacy of BMS-180194 against experimental cytomegalovirus infections in immunocompromised mice